Predicting the outcome of peptide receptor radionuclide therapy in neuroendocrine tumors: the importance of dual-tracer imaging

Paolo Zanotti-Fregonara, Clément Morgat, Christophe Champion, Elif Hindié
Eur J Nucl Med Mol Imaging. 2017-03-10; 44(6): 1095-1096
DOI: 10.1007/s00259-017-3667-7


Lire sur PubMed

---

1. Eur J Nucl Med Mol Imaging. 2017 Jun;44(6):1095-1096. doi:
10.1007/s00259-017-3667-7. Epub 2017 Mar 10.

Predicting the outcome of peptide receptor radionuclide therapy in neuroendocrine
tumors: the importance of dual-tracer imaging.

Zanotti-Fregonara P(1), Morgat C(2), Champion C(3), Hindié E(2).

Author information:
(1)Houston Methodist Research Institute, Houston, TX, USA. .
(2)Service de Médecine Nucléaire – CHU de Bordeaux; UMR-CNRS 5287; LabEx TRAIL,
Université de Bordeaux, Bordeaux, France.
(3)CNRS/IN2P3, Centre d’Etudes Nucléaires de Bordeaux Gradignan (CENBG),
Université de Bordeaux, Bordeaux, France.

Comment in
Eur J Nucl Med Mol Imaging. 2017 Sep;44(10 ):1777-1778.

Comment on
Eur J Nucl Med Mol Imaging. 2017 Mar;44(3):490-499.

DOI: 10.1007/s00259-017-3667-7
PMID: 28283701 [Indexed for MEDLINE]

Auteurs Bordeaux Neurocampus